Correlation Between Monthly Rebalance and Pharmaceuticals Ultrasector

Can any of the company-specific risk be diversified away by investing in both Monthly Rebalance and Pharmaceuticals Ultrasector at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monthly Rebalance and Pharmaceuticals Ultrasector into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Monthly Rebalance Nasdaq 100 and Pharmaceuticals Ultrasector Profund, you can compare the effects of market volatilities on Monthly Rebalance and Pharmaceuticals Ultrasector and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monthly Rebalance with a short position of Pharmaceuticals Ultrasector. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monthly Rebalance and Pharmaceuticals Ultrasector.

Diversification Opportunities for Monthly Rebalance and Pharmaceuticals Ultrasector

0.77

Correlation Coefficient

Monthly Rebalance  Pharmaceuticals Ultrasector

Poor diversification

The 3 months correlation between Monthly and Pharmaceuticals is 0.77. Overlapping area represents the amount of risk that can be diversified away by holding Monthly Rebalance Nasdaq 100 and Pharmaceuticals Ultrasector Pr in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pharmaceuticals Ultrasector and Monthly Rebalance is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monthly Rebalance Nasdaq 100 are associated (or correlated) with Pharmaceuticals Ultrasector. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pharmaceuticals Ultrasector has no effect on the direction of Monthly Rebalance i.e., Monthly Rebalance and Pharmaceuticals Ultrasector go up and down completely randomly.

Pair Corralation between Monthly Rebalance and Pharmaceuticals Ultrasector

Assuming the 90 days horizon Monthly Rebalance Nasdaq 100 is expected to generate 0.98 times more return on investment than Pharmaceuticals Ultrasector. However, Monthly Rebalance Nasdaq 100 is 1.02 times less risky than Pharmaceuticals Ultrasector. It trades about 0.37 of its potential returns per unit of risk. Pharmaceuticals Ultrasector Profund is currently generating about 0.09 per unit of risk. If you would invest  39,394  in Monthly Rebalance Nasdaq 100 on April 23, 2025 and sell it today you would earn a total of  19,958  from holding Monthly Rebalance Nasdaq 100 or generate 50.66% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	98.39%
Values	Daily Returns

Monthly Rebalance Nasdaq 100  vs.  Pharmaceuticals Ultrasector Pr

Monthly Rebalance

Risk-Adjusted Performance

Strong

Compared to the overall equity markets, risk-adjusted returns on investments in Monthly Rebalance Nasdaq 100 are ranked lower than 29 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak basic indicators, Monthly Rebalance showed solid returns over the last few months and may actually be approaching a breakup point.

Pharmaceuticals Ultrasector

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Pharmaceuticals Ultrasector Profund are ranked lower than 7 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak forward indicators, Pharmaceuticals Ultrasector may actually be approaching a critical reversion point that can send shares even higher in August 2025.

Pair Trading with Monthly Rebalance and Pharmaceuticals Ultrasector

The main advantage of trading using opposite Monthly Rebalance and Pharmaceuticals Ultrasector positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monthly Rebalance position performs unexpectedly, Pharmaceuticals Ultrasector can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharmaceuticals Ultrasector will offset losses from the drop in Pharmaceuticals Ultrasector's long position.

The idea behind Monthly Rebalance Nasdaq 100 and Pharmaceuticals Ultrasector Profund pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.